Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Future Oncol. 2015 Mar;11(5):865–878. doi: 10.2217/fon.14.312

Figure 2. Protein–protein interaction inhibition method for the development of drugs for different types of EGF receptor-overexpressed cancer.

Figure 2

The extracellular domains of EGFR and HER2 are shown as heterodimers. Note that domain IV is involved in the interaction of two proteins. Domain IV can be targeted with small molecules, peptides or peptidomimetics for the inhibition of dimerization. The region of PPI and its inhibition is marked by an oval shape. The model of EGFR:HER2 heterodimer was generated [108,109] using the crystal structures of EGFR (PDB ID 3NJP) [110] and HER2 (PDB ID) [111] with a homodimer of EGFR as a template (PDB ID 3NJP). EGFR: EGF receptor; PPI: Protein–protein interaction.